Maralixibat Disease Interactions

Liver function test (LFT) abnormalities included ALT, AST, and/or total/direct bilirubin elevations and occurred in patients given maralixibat. Maralixibat was not tested in patients with clinically significant portal hypertension, decompensated cirrhosis, and/or hepatic decompensation. Baseline LFTs should be obtained prior to starting treatment, and levels should be monitored throughout treatment. Dose adjustments should be considered in patients who develop LFT abnormalities in the absence of alternative etiologies. Treatment discontinuation should be considered in patients with persistent or recurrent LFT abnormalities.

Maralixibat may affect fat-soluble vitamin (FSV [e.g., vitamins A, D, E, K]) absorption. Baseline FSV levels should be obtained prior to starting treatment, and levels should be monitored throughout treatment. Patients should undergo supplementation with FSV if a deficiency is diagnosed, and treatment discontinuation should be considered in patients with persistent or worsening FSV deficiency despite supplementation.